Altimmune (ALT) News Today $3.63 +0.04 (+1.11%) Closing price 04:00 PM EasternExtended Trading$3.62 -0.01 (-0.28%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is Altimmune Up Today?Toggle Visibility of Why Is Altimmune Up Today?Altimmune, Inc. (NASDAQ: ALT) Recent News Summary Positive Sentiment: Altimmune appointed Linda M. Richardson as Chief Commercial Officer, leveraging her 30+ years of sales, marketing and business development experience to advance Phase 3 commercialization of lead candidate pemvidutide.Altimmune Appoints Accomplished Commercial Executive Negative Sentiment: Multiple law firms—including Rosen Law Firm, Levi & Korsinsky, The Gross Law Firm and Bragar Eagel & Squire—have filed or notified investors of securities class-action lawsuits against Altimmune, reminding shareholders of upcoming lead-plaintiff deadlines and underscoring litigation risk.Rosen Law Firm Encourages Investors to Secure Counsel Posted 3h agoAI Generated. May Contain Errors. ALT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT5 hours ago | prnewswire.comShareholders that lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class Action - ALTSeptember 16 at 5:17 PM | globenewswire.comShareholders That Lost Money on Altimmune, Inc. (ALT) Should Contact Levi & Korsinsky About Pending Class Action - ALTSeptember 16 at 10:20 AM | theglobeandmail.comAltimmune appoints Richardson as Chief Commercial OfficerSeptember 16 at 10:20 AM | msn.comLevi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALTSeptember 16 at 8:45 AM | prnewswire.comROSEN, NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTSeptember 15 at 7:03 PM | globenewswire.comAltimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALTSeptember 15 at 8:45 AM | prnewswire.comAltimmune, Inc. Appoints Linda M. Richardson as Chief Commercial OfficerSeptember 15 at 7:50 AM | quiverquant.comQAltimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial OfficerSeptember 15 at 7:30 AM | globenewswire.comBragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the FirmSeptember 15 at 7:14 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALTSeptember 14 at 10:00 AM | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneSeptember 13 at 10:20 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALTSeptember 13 at 10:00 AM | prnewswire.comROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTSeptember 12, 2025 | globenewswire.comClass Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for Investors - Contact Levi & KorsinskySeptember 12, 2025 | theglobeandmail.comClass Action Filed Against Altimmune, Inc. – Investors with Losses Encouraged to Contact Johnson FistelSeptember 12, 2025 | globenewswire.comLevi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALTSeptember 12, 2025 | prnewswire.comALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud LawsuitSeptember 11, 2025 | prnewswire.comFaruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALTSeptember 11, 2025 | globenewswire.comShareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights – ALTSeptember 11, 2025 | globenewswire.comAltimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALTSeptember 11, 2025 | prnewswire.comALT LAWSUIT ALERT: Levi & Korsinsky Notifies Altimmune, Inc. Investors - Lead Plaintiff Deadline October 6, 2025September 11, 2025 | theglobeandmail.comAltimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comThe Gross Law Firm Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming DeadlineSeptember 10, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALTSeptember 10, 2025 | globenewswire.comALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 10, 2025 | globenewswire.comLost Money on Altimmune, Inc. (ALT)? Contact Levi & Korsinsky Before October 6, 2025 to Join Class ActionSeptember 10, 2025 | theglobeandmail.comLevi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 6, 2025 - ALTSeptember 10, 2025 | theglobeandmail.comAltimmune: Pemvidutide Shows Promise In MASH, But Lacks Competitive EdgeSeptember 10, 2025 | seekingalpha.comROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTSeptember 9, 2025 | globenewswire.comAltimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALTSeptember 9, 2025 | prnewswire.comClass Action Filed Against Altimmune, Inc. (ALT) - October 6, 2025 Deadline to Join - Contact Levi & KorsinskySeptember 8, 2025 | theglobeandmail.comLost Money on Altimmune, Inc. (ALT)? Join Class Action Before October 6, 2025 - Contact Levi & KorsinskySeptember 8, 2025 | theglobeandmail.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune Lawsuit – ALTSeptember 8, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALTSeptember 8, 2025 | prnewswire.comThe Gross Law Firm Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALTSeptember 8, 2025 | prnewswire.comAltimmune, Inc. $ALT Shares Sold by Invesco Ltd.September 8, 2025 | marketbeat.comFaruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALTSeptember 7, 2025 | globenewswire.comALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud LawsuitSeptember 6, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALTSeptember 6, 2025 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AltimmuneSeptember 6, 2025 | prnewswire.comHsbc Holdings PLC Acquires New Holdings in Altimmune, Inc. $ALTSeptember 6, 2025 | marketbeat.comROSEN, NATIONAL TRIAL LAWYERS, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTSeptember 5, 2025 | markets.businessinsider.comROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALTSeptember 5, 2025 | globenewswire.comLevi & Korsinsky Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALTSeptember 5, 2025 | prnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALTSeptember 4, 2025 | theglobeandmail.comALT5 Sigma Corporation Announces $WLFI Holdings Rise to Approximately 7.28 Billion TokensSeptember 4, 2025 | businesswire.comLost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law FirmSeptember 4, 2025 | prnewswire.comContact Levi & Korsinsky by October 6, 2025 Deadline to Join Class Action Against Altimmune, Inc. (ALT)September 3, 2025 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALTSeptember 3, 2025 | prnewswire.com Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALT Media Mentions By Week ALT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼0.260.92▲Average Medical News Sentiment ALT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼298▲ALT Articles Average Week Get the Latest News and Ratings for ALT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Altimmune and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Evotec News Intellia Therapeutics News Arcus Biosciences News Pharvaris News Tourmaline Bio News CureVac News Zymeworks News Dianthus Therapeutics News 89BIO News Xeris Biopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
